Abstract
Direct-acting antivirals (DAAs) have dramatically changed the treatment of chronic hepatitis C. Their high efficacy helps in eradicating hepatitis C virus with few adverse events. Information on real-world use of DAAs therapy in patients aged 75 years and older is inadequate. The Japanese DAAs database was constructed in 2014 as a cooperative system between 18 prefectures. The medical reports filled in by doctors and anonymized at the local government office were collected. The patients' demographic features, viral factors, and treatment characteristics were compared among three groups stratified by age when therapy was initiated: Group A (<60 years old), Group B (60-74 years old), and Group C (≥75 years old). Out of the 22,454 patients whose age upon starting therapy could be identified, 24.8% (n = 5597) belonged to Group C, which was ten times the number in the Japanese Interferon Database. Female patients, advanced stages of liver fibrosis, and past history of hepatocellular carcinoma treatment were significantly higher in the older age groups (Group A < B < C), whereas sustained virologic response (SVR) rates were not different (91%-93%). In Group C, multivariate logistic regression analysis revealed that predicting factors...Continue Reading
References
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Richard K SterlingUNKNOWN APRICOT Clinical Investigators
Dec 15, 2010·Journal of Hepatology·Tsugiko OzeNorio Hayashi
Jan 4, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yu ShimoyamaKatsuaki Tanaka
Mar 8, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hiromitsu KumadaEric Hughes
Sep 10, 2014·Journal of Viral Hepatitis·Masao OmataMasashi Mizokami
Feb 4, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kazuaki ChayamaHiromitsu Kumada
Apr 13, 2015·The Lancet Infectious Diseases·Masashi MizokamiMasao Omata
Jun 20, 2015·BMC Public Health·Naohiko MasakiUNKNOWN prefectural members contributing to the Japanese Interferon Database
May 5, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study(KULDS) Group
Nov 2, 2016·Journal of Medical Virology·Norio AkutaHiromitsu Kumada
Jun 14, 2016·Alimentary Pharmacology & Therapeutics·L I BackusL A Mole
Oct 30, 2016·Antiviral Research·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
Nov 22, 2016·Journal of Gastroenterology and Hepatology·D Steven FoxJeffrey S McCombs
Nov 23, 2016·Journal of Gastroenterology·Hiromitsu KumadaJanice Wahl
Feb 15, 2017·European Journal of Gastroenterology & Hepatology·Feng SuGeorge N Ioannou
Jun 20, 2017·Journal of Hepatology·Hiroko NagataUNKNOWN Ochanomizu Liver Conference Study Group
Aug 11, 2017·PloS One·Yuko NagaokiKazuaki Chayama
Sep 3, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hidenori ToyodaHiromitsu Kumada
Sep 28, 2017·Journal of Gastroenterology·Kazuaki ChayamaHiromitsu Kumada
Apr 8, 2018·Journal of Gastroenterology·Keiji TsujiNamiki Izumi
Oct 20, 2018·Journal of Hepatology·Mizuki Nishibatake KinoshitaKazuhiko Koike
Jan 9, 2019·JGH Open : an Open Access Journal of Gastroenterology and Hepatology·Hideyuki TamaiKatsuhiko Higashi
May 28, 2019·Open Forum Infectious Diseases·Hidenori ToyodaTakashi Kumada
Nov 21, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hiroko SetoyamaTatsuya Kanto
Dec 10, 2019·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marc G GhanyUNKNOWN AASLD-IDSA Hepatitis C Guidance Panel
Oct 31, 2019·Global Health & Medicine·Yuko KitayamaTatsuya Kanto